by Tomomi Kogiso  , Mutsuki Kobayashi  , Kuniko Yamamoto  , Yuichi Ikarashi  , Kazuhisa Kodama  , Makiko Taniai  , Nobuyuki Torii  , Kazunari Tanabe  , Hideki Ishida  , Shohei Fuchinoue  , Hiroto Egawa  , Masakazu Yamamoto  , Etsuko Hashimoto  and Katsutoshi Tokushige

Received: 08 February 2017;  Published: 06 April 2017;  doi: 10.21926/obm.hg.1702003

Background: Hepatitis C virus (HCV) infection frequently occurs in recipients of liver or kidney transplants (LT/KT). Interferon (IFN)-based therapies are used to treat HCV, but their efficacy is low. Methods: We report 24 patients who received HCV therapy after LT/KT. Design, Setting, and Participants-Twelve LT and 12 KT recipients (median age, 59 years; 15 males; 21 serological type 1) were enrolled, of whom eight (six with LT) were treated with IFN-based therapy. Twelve received direct-acti [...]